Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives

被引：44

作者：

Atallah-Yunes, Suheil Albert ^{[1
]}

Robertson, Michael J. ^{[1
]}

机构：

[1] Indiana Univ Sch Med, Dept Hematol & Med Oncol, Indianapolis, IN 46202 USA

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

cytokines; immunotherapy; interleukins; cancer; lymphoma; RECOMBINANT HUMAN INTERLEUKIN-12; NON-HODGKINS-LYMPHOMA; NATURAL-KILLER-CELLS; ALPHA-2 INTERFERON THERAPY; IN-VIVO; PHASE-I; DOSE-ESCALATION; NK CELLS; COMBINATION; RITUXIMAB;

D O I：

10.3389/fimmu.2022.872010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cytokines regulate both the innate and adaptive immune responses to cancer. Although antitumor activity has been seen for several cytokines in preclinical models, they have had limited success as single therapeutic agents in clinical trials of cancer immunotherapy. However, the possible combinations of cytokines with other immune therapeutics and the advancement in genetic engineering, synthetic biology and cellular and immune therapy has led to the revival of interest in cytokines as anticancer agents. This article will review several immunostimulatory cytokines with anticancer activity, focusing on the those that have been studied in treatment of lymphoma and highlighting recent advances of potential clinical relevance.

引用

页数：10

共 104 条

[1] SPONTANEOUS PRODUCTION OF ALPHA-INTERFERON AND BETA-INTERFERON IN HUMAN-LYMPHOBLASTOID AND LYMPHOMA CELL-LINES [J].

ADOLF, GR ;

HAAS, OA ;

FISCHER, P ;

SWETLY, P .

ARCHIVES OF VIROLOGY, 1982, 72 (03) :169-178

[2]

Amer Magid H, 2014, Mol Cell Ther, V2, P27

[3] A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12 [J].

Angiolillo, AL ;

Sgadari, C ;

Tosato, G .

INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 :158-167

[4] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma [J].

Ansell, SM ;

Witzig, TE ;

Kurtin, PJ ;

Sloan, JA ;

Jelinek, DF ;

Howell, KG ;

Markovic, SN ;

Habermann, TM ;

Klee, GG ;

Atherton, PJ ;

Erlichman, C .

BLOOD, 2002, 99 (01) :67-74

[5] Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients [J].

Ansell, Stephen M. ;

Geyer, Susan M. ;

Maurer, Matthew J. ;

Kurtin, Paul J. ;

Micallef, Ivana N. M. ;

Stella, Philip ;

Etzell, Paul ;

Novak, Anne J. ;

Erlichman, Charles ;

Witzig, Thomas E. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6056-6063

[6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[7]

Atkins MB, 1997, CLIN CANCER RES, V3, P409

[8] Allogeneic natural killer cells for refractory lymphoma [J].

Bachanova, Veronika ;

Burns, Linda J. ;

McKenna, David H. ;

Curtsinger, Julie ;

Panoskaltsis-Mortari, Angela ;

Lindgren, Bruce R. ;

Cooley, Sarah ;

Weisdorf, Daniel ;

Miller, Jeffrey S. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) :1739-1744

[9]

Bajetta E, 1998, CLIN CANCER RES, V4, P75

[10] IL-21 Contributes to JAK3/STAT3 Activation and Promotes Cell Growth in ALK-Positive Anaplastic Large Cell Lymphoma [J].

Bard, Jennifer Dien ;

Gelebart, Pascal ;

Anand, Mona ;

Zak, Zoulika ;

Hegazy, Samar A. ;

Amin, Hesham M. ;

Lai, Raymond .

AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (02) :825-834

← 1 2 3 4 5 6 7 8 9 10 →